We are live on ! Find out more
SAGE

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

193 hedge funds and large institutions have $581M invested in Sage Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 76 increasing their positions, 54 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

363% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $2.18M

41% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 54

5% less funds holding

Funds holding: 204193 (-11)

8.37% less ownership

Funds ownership: 97.3%88.92% (-8.4%)

20% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 40

47% less capital invested

Capital invested by funds: $1.1B → $581M (-$516M)

Holders
193
Holders Change
-11
Holders Change %
-5.39%
% of All Funds
2.79%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
32
Increased
76
Reduced
54
Closed
40
Calls
$10.1M
Puts
$2.18M
Net Calls
+$7.92M
Net Calls Change
+$5.82M
Name Holding Trade Value Shares
Change
Change in
Stake
EIP
51
Easterly Investment Partners
Massachusetts
$1.48M +$346K +27,000 +25%
Walleye Capital
52
Walleye Capital
New York
$1.4M +$800K +62,428 +94%
Rafferty Asset Management
53
Rafferty Asset Management
New York
$1.34M -$3.45M -269,166 -69%
HF
54
HRT Financial
New York
$1.29M +$1.53M +119,332 New
JGC
55
J. Goldman & Co
New York
$1.27M +$1.5M +116,842 New
Russell Investments Group
56
Russell Investments Group
United Kingdom
$1.26M +$960K +74,942 +181%
DCM
57
DAFNA Capital Management
California
$1.26M +$1.49M +116,200 New
Marshall Wace
58
Marshall Wace
United Kingdom
$1.18M +$1.39M +108,439 New
AQR Capital Management
59
AQR Capital Management
Connecticut
$1.01M +$1.2M +93,830 New
RhumbLine Advisers
60
RhumbLine Advisers
Massachusetts
$988K +$174K +13,573 +18%
Swiss National Bank
61
Swiss National Bank
Switzerland
$962K -$226K -17,600 -17%
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$936K -$69.5K -5,428 -6%
UBS AM
63
UBS AM
Illinois
$892K +$277K +21,611 +36%
GCP
64
GSA Capital Partners
United Kingdom
$855K +$860K +67,094 +576%
Barclays
65
Barclays
United Kingdom
$854K +$9.02K +704 +0.9%
SSA
66
Schonfeld Strategic Advisors
New York
$747K +$881K +68,752 New
AG
67
Algert Global
California
$704K +$501K +39,114 +152%
Aberdeen Group
68
Aberdeen Group
United Kingdom
$704K
Baillie Gifford & Co
69
Baillie Gifford & Co
United Kingdom
$688K -$224K -17,483 -22%
AllianceBernstein
70
AllianceBernstein
Tennessee
$664K
Legal & General Group
71
Legal & General Group
United Kingdom
$642K -$8.81K -688 -1%
TD Asset Management
72
TD Asset Management
Ontario, Canada
$624K -$664K -51,800 -47%
EGM
73
Engineers Gate Manager
New York
$579K +$389K +30,394 +133%
Ohio Public Employees Retirement System (OPERS)
74
Ohio Public Employees Retirement System (OPERS)
Ohio
$568K +$670K +52,285 New
GCM
75
Graham Capital Management
Connecticut
$536K +$633K +49,366 New

SAGE Hedge Fund Activity: Q2 2024 in Review

193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2024, worth a combined $581M — down 47% from $1.1B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of SAGE and 32 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 76 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $11.1M. The largest seller was Wellington Management Group, cutting an estimated $60.4M.

  • 193 institutional investors held Sage Therapeutics (SAGE) as of Q2 2024, down from 204 in Q1 2024.
  • Funds reported $581M of Sage Therapeutics stock for Q2 2024, down 47% quarter-over-quarter.
  • 32 funds opened new Sage Therapeutics positions in Q2 2024 and 40 closed out, a net change of -8 holders.
  • The largest Sage Therapeutics buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $11.1M added.
  • The largest Sage Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $60.4M sold.

Based on aggregated 13F filings for Q2 2024.